New Therapeutic Interventions in Airway Inflammatory and Allergic Diseases

Asthma is a common, chronic condition that is usually treated by the combination of inhaled steroids and β2 agonists on a when required basis. More recently, two further agents have been licensed for use: leukotriene receptor antagonists and very recently anti-IgE. This review describes a number of other possible treatment modalities. Some are well developed and already in Phase III clinical trials, others involve the use of drugs already on the market for other indications and a number are reasonably speculative.